异基因造血干细胞移植治疗难治复发急性髓系白血病热点问题

冯四洲; 姜尔烈

异基因造血干细胞移植治疗难治复发急性髓系白血病热点问题

冯四洲^,,
姜尔烈

- 中国医学科学院北京协和医学院血液学所血液病医院(天津, 300020)

详细信息

通讯作者: 冯四洲,E-mail:sizhoufeng@medmail.com.cn

中图分类号: R733.71

收稿日期: 2013-07-19

Corresponding author: , E-mail: sizhoufeng@medmail.com.cn

Received Date: 19 July 2013

摘要

- 难治复发 /
- 白血病,髓系,急性 /
- 治疗

HTML全文

参考文献(14)

[1]	BREEMS D A,VAN PUTTEN W L,HUIJGENS P C,et al.Prognostic index for adult patients with acute myeloid leukemia in first relapse[J].J Clin Oncol,2005,23:1969-1678.
[2]	CHEVALLIER P,LABOPIN M,TURLURE P,et al.A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients:a GOELAMS study[J].Leukemia,2011,25:939-944.
[3]	RAVANDI F,CORTES J,FADERL S,et al.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy[J].Blood,2010,116:5818-5823.
[4]	FELDMAN E J,LANCET J E,KOLITZ J E,et al.First-in-man study of CPX-351:a liposomal carrier containing cytarabine and daunoru-bicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia[J].J Clin Oncol,2011,29:979-985.
[5]	OYEKUNLE A A,KRÖGER N,ZABELINA T,et al.Allogeneic stem-cell transplantation in patients with refractory acute leukemia:a long-term follow-up[J].Bone Marrow Transplant,2006,37:45-50.
[6]	DUVAL M,KLEIN J P,HE W,et al.Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure[J].J Clin Oncol,2010,28:3730-3738.
[7]	SCHMID C,SCHLEUNING M,SCHWERDTFEG-ER R,et al.Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation[J].Blood,2006,108:1092-1099.
[8]	ROWE J M,TALLMAN M S.How I treat acute myeloid leukemia[J].Blood,2010,116:3147-3156.
[9]	FERRARA F,FAZI P,VENDITTI A,et al.Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia:a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party[J].Hematol Oncol,2008,26:104-107.
[10]	LITZOW M R,OTHUS M,CRIPE L D,et al.Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia:a report from the Eastern Cooperative Oncology Group[J].Br J Haematol,2010,148:217-225.
[11]	SCHNEIDAWIND D,FEDERMANN B,FAUL C,et al.Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia[J].Ann Hematol,2013.[Epub ahead of print].
[12]	CHEMNITZ J M,VON LILIENFELD-TOAL M,HOLTICK U,et al.Intermediate intensity conditioning regimen containing FLAMSA,treosulfan,cyclophosphamide,and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia[J].Ann Hematol,2012,91:47-55.
[13]	GERGIS U,MCKENNA M,RITCHIE E,et al.A novel sequential treatment utilizing CPX-351 as salvage chemotherapy followed by a reduced intensity conditioning allogeneic stem-cell transplantation for patients with refractory leukemia[J].Biol Blood Marrow Transplant (Suppl),2011,17:S305-S306.
[14]	SCATENA C D,KUMER J L,ARBITRARIO J P,et al.Voreloxin,a first-in-class anticancer quinolone derivative,acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo[J].Cancer Chemother Pharmacol,2010,66:881-888.